Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat for Portal Hypertension in Compensated Cirrhosis
NCT05161481Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of avenciguat in Portal Hypertension (PH) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage Change in Hepatic Venous Pressure Gradient From Baseline at 24 weeks. Started Apr 2022; status: terminated.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT05161481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161481.